We will help you navigate through the challenges of reimbursement and funding for medical devices and in-vitro diagnostics in Europe

MTRC is a provider of on-demand and off-the-shelf European reimbursement analysis and strategy for industry and investment companies

News and blog posts

Stay up-to-date about developments of reimbursement systems in Europe

19 Sep 2017
NHS Improvement together with providers of pathology (laboratory) services in England determined ways to integrate laboratory services to increase efficiency and reduce cost. The final proposal includes integration of pathology services of 105 English hospitals into 29 pathology networks, which would save NHS up to £200m annually.


Nov 2017

After successful trial application by a manufacturer (St. Jude Medical, now part of Abbott), the Federal Joint Committee (G-BA) decided to conduct a co-funded study to create evidence about the measurement and monitoring of pulmonary artery pressure using an implanted sensor called “CardioMEMS™ HF System” to optimize therapy in NYHA III heart failure. The G-BA released a trial guideline defining the key points of the planned study, including type and duration of the study, target population and control intervention.


Nov 2017

The Clinical Coding and Schedule Development Group develops and maintains procedural and diagnostics nomenclature for private payers in England. New codes were added for trans-oral robotic surgery and joint replacement surgery.


Nov 2017

A manufacturer (PQ Bypass) requested a consultation by the Joint Federal Committee (G-BA) about the eligibility of their medical device for an early benefit assessment according to §137h of the Social Code Book V (SGB V). The technology (PQ Bypass Stent Graft System) is a fully-percutaneous femoral-popliteal bypass procedure for peripheral arterial disease. The G-BA argued that the method is not based on the use of a high-risk medical device and therefore does not have to undergo a §137h assessment.


Nov 2017

Patients should not pay anything other than regulated out-of-pocket payments when they visit general practitioner or other healthcare professional, who have contract with public health authorities.

About us

We are a group of enthusiasts who are passionate about the areas of health policy, evidence generation, reimbursement and funding for medical technologies. We have turned our passion into a career. More specifically, we develop insights which help our customers optimize their business decisions

Our company is based in Stockholm, Sweden

The founder of company is Oleg Borisenko, one of the leading experts on European market access for medical devices. With more than 11 years of experience in the field, Oleg has led several hundred of projects. These include reimbursement analyses and strategies, value dossiers, health economic models and evidence generation strategies

Our team consists of six clinical coders and market analysts, including four medical doctors and one pharmacist. Three of our members have PhD degrees in different areas of clinical and public health science

Our unique proposition is Pan-European reimbursement mapping and strategy projects for the Med Tech and IVD industries. To match the requirements and budget of our various customers, we approach their needs differently: from low-cost off-the-shelf reimbursement reports for dozens of medical technologies to full scale reimbursement and evidence generation projects

We provide analyses for 14 European countries

Check out our database of the off-the-shelf reimbursement reports for medical technologies in 11 European countries

Released reports:

  • Transcatheter aortic valve implantation (TAVI) 
  • Eight minimally invasive and transcatheter mitral valve repair and replacement technologies
  • Group of peripheral vascular arterial interventions (angioplasty, angioplasty using drug-eluting balloon, stenting using bare metal and drug-eluting stents, atherectomy, periperal IVUS)
  • Robotic surgery interventions
  • Peripheral venous interventions for deep vein thrombosis and venous insufficiency

Reports scheduled for release in September-December 2017:

  • Coronary percutaneous revascularization and imaging procedures (including PCI using bare metal, drug-eluting and bioabsorbable stents, IVUS, FFR, thrombectomy)
  • Mechanical thrombectomy for stroke
  • Ablation of heart tissue for atrial fibrillation
  • Procedures on spine for intervertebral disc prolapse, vertebra fracture
  • Interventional procedure for gastro-esophageal reflux disease